Skip to main content

From the helm: Botanix Phamaceuticals (ASX:BOT) CEO, Dr Howie McKibbon

Bell Direct
October 9, 2024

In this episode of our From the helm series, Bell Direct’s Grady Wulff speaks with Dr. Howie McKibbon, CEO of Botanix Pharmaceuticals (ASX:BOT). Based in Philadelphia, Botanix is a dermatology company focused on advancing its lead product, Sofdra, which is FDA-approved for the treatment of primary axillary hyperhidrosis. With the successful commercialisation of Sofdra, the company is positioned in a growing market.

Dr. McKibbon joins us to discuss the latest developments and outlook for Botanix,. In this conversation, he covers:

  • (0:42) an overview of Botanix Pharmaceuticals for investors who may not be familiar with the company
  • (1:28) the significance of Sofdra’s FDA approval and the global market potential for its treatment
  • (2:48) the competitive landscape within the dermatology space
  • (3:45) how Botanix manages costs during the later stages of clinical trials and the factors contributing to its financial strength
  • (4:30) insights into what the next 12 months hold for Botanix.

Note: This interview was recorded at the ASX Small to Mid-Cap Conference on 25 September 2024.

Morning Bell 20 February

Grady Wulff
February 20, 2024

Morning Bell 19 February

Grady Wulff
February 19, 2024

Weekly Wrap 16 February

Sophia Mavridis
February 16, 2024

Morning Bell 16 February

Sam Kanaan
February 16, 2024

Morning Bell 15 February

Sam Kanaan
February 15, 2024

Morning Bell 14 February

Sam Kanaan
February 14, 2024

Morning Bell 13 February

Grady Wulff
February 13, 2024

Morning Bell 12 February

Grady Wulff
February 12, 2024

Weekly Wrap 9 February

Grady Wulff
February 9, 2024

Morning Bell 9 February

Sam Kanaan
February 9, 2024